# Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry: Guidance for Industry - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/cannabis-and-cannabis-derived-compounds-quality-considerations-for-clinical-research-guidance-for-industry-guidance-for-industry/529cc738-130c-4b4d-afb4-d2ea5f0fe894 > FDA guidance document: Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry: Guidance for Industry. Issue date: January 23, 2023. Get complete insights and analysis. --- ## Details - Title: Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry: Guidance for Industry - Communication Type: Guidance Document - Product Type: drugs - Office Name: Center for Drug Evaluation and Research - Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c - Issue Date: 2023-01-23 - Last Changed: 2024-03-28 - Docket Number: FDA-2020-D-1079 ## Related Documents - [Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/questions-and-answers-on-quality-related-controlled-correspondence-guidance-for-industry-guidance-for-industry/36e0e984-b134-47b6-bee8-6f25aa0282c1) - [Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-drug-interaction-studies-with-combined-oral-contraceptives-guidance-for-industry-guidance-for-industry/66dca3d2-f3c0-447f-8085-fd2e7ebd60c6) - [ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions](https://www.globalkeysolutions.net/guidances/guidance-document/andas-pre-submission-facility-correspondence-related-to-prioritized-generic-drug-submissions/44de7e09-5433-4834-a1c2-11c6a384c15e)